Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 18, Issue 3, 2004, Pages 353-365

  Bukaveckas, Bonny L ^a   Valdes Jr , Roland ^a   Linder, Mark W ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

2 adrenergic receptor; AC9; adenylyl cyclase type 9; anesthesia; B2AR; BChE; BIS; bispectral index; butyrylcholinesterase; cardiovascular; CYP; cytochrome P450; drug metabolism; EM; extensive metabolizer; genetic polymorphism; IM; pharmacogenetics

Indexed keywords

AMRINONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; IRBESARTAN; LABETALOL; LERCANIDIPINE; LISINOPRIL; LOSARTAN; METOPROLOL; NADOLOL; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PINDOLOL; PROPRANOLOL DERIVATIVE; TIMOLOL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ALLELE; BLOOD LEVEL; CHROMOSOME; DIAGNOSTIC PROCEDURE; DNA ISOLATION; ENZYME ACTIVITY; GENE STRUCTURE; GENERAL ANESTHESIA; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; KARYOTYPE; MALIGNANT HYPERTHERMIA; MEDICAL PRACTICE; METABOLIC CAPACITY; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ANESTHETICS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR SURGICAL PROCEDURES; CYTOCHROME P-450 ENZYME SYSTEM; GENES, MDR; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; VARIATION (GENETICS);

EID: 3042568917     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2004.03.019     Document Type: Review

References (147)

1. Anderson J.L., Carlquist J.F., Horne B.D., et al. Cardiovascular pharmacogenomics Current status, future perspectives. J Cardiovasc Pharmacol Therapeut. 8:2003;71-83
2. Meisel C., Roots I., Cascorbi I., et al. How to manage individualized drug therapy Application of pharmacocogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med. 38:2000;869-876
3. den Dunnen J.T., Antonarakis E. Nomenclature for the description of human sequence variations. Hum Genet. 109:2001;121-124
4. Hayashi S., Watanabe J., Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the Human Cytochrome P450IIE1 gene. J Biochem (Tokyo). 110:1991;559-565
5. Qiu L., Linder M.W., Antonino-Green D., et al. Suppression of cytochrome P4502E1 promoter activity by interferon-γ and loss of response due to the-71G>T nucleotide polymorphism of the CYP2E1*7B allele. J Pharmacol Exp Ther. 308:2004;284-288
6. Hanselle T., Otte M., Schnibbe T., et al. Isolation of genomic DNA from buccal swabs for forensic analysis, using fully automated silica-membrane purification technology. Leg Med (Tokyo). 5:(suppl 1):2003;S145-149
7. May S. Strategies for medium-throughput automated genotyping methods. Psychiatr Genet. 12:2002;127-132
8. Saffroy R., Lemoine A., Haas P., et al. Rapid automated simultaneous screening of (G1691A) Factor V, (G20210A) prothrombin, and (C677T) methylenetetrahydrofolate reductase variants by multiplex PCR using fluorescence scanning technology. Genet Test. 6:2002;233-236
9. Li Q., Liu Z., Monroe H., et al. Integrated platform for detection of DNA sequence variants using capillary array electrophoresis. Electrophoresis. 23:2002;1499-1511
10. Brennan M.D. High-throughput genotyping technologies for pharmacogenomics. Am J Pharmacogenomics. 1:2001;295-302
11. Rae J.M., Cordero K.E., Scheys J.O., et al. Genotyping for polymorphic drug-metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics. 13:2003;501-507
12. Liljedahl U., Karlsson J., Melhus H., et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics. 13:2003;7-17
13. Andrisin T.E., Humma L.M., Johnson J.A. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy. 22:2002;954-960
14. Pillans P.I. Increasing relevance of pharmacogenetics of drug metabolism in clinical practice. Intern Med J. 31:2001;476-478
15. Williams L.O., Cole E.C., Lubin I.M., et al. Quality assurance in human molecular genetics testing Status and recommendations. Arch Pathol Lab Med. 127:2003;1353-1358
16. Amos J., Patnaik M. Commercial molecular diagnostics in the U.S The Human Genome Project to the clinical laboratory. Hum Mutat. 19:2002;324-333
17. Agundez J.A.G., Ledesma M.C., Ladero J.M., et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther. 57:1995;265-269
18. Barker P.E., Watson M.S., Ticehurst J.R., et al. NIST physical standards for DNA-based medical testing. J Clin Lab Anal. 16:2002;5-10
19. Kudzma E.C. Cultural competence Cardiovascular medications. Prog Cardiovasc Nurs. 16:2001;152-160. 169
20. Lee A., Gin T., Oh T.E. Opioid requirements and responses in Asians. Anaesth Intensive Care. 25:1997;665-670
21. Murthy B.R., Pollack G.M., Brouwer K.L. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol. 42:2002;569-576
22. Williams D.G., Patel A., Howard R.F. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth. 89:2002;839-845
23. Tuteja S., Alloway R.R., Johnson J.A., et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation. 71:2001;1303-1307
24. Lamberg L. Venus orbits closer to pain than Mars, Rx for one sex may not benefit the other. JAMA. 280:1998;120-124
25. Sachse C., Brockmoller J., Bauer S., et al. Cytochrome P450 2D6 variants in a Caucasian population Allele frequencies and phenotypic consequences. Am J Hum Genet. 60:1997;284-295
26. Flores C.M., Mogil J.S. The pharmacogenetics of analgesia Toward a genetically-based approach to pain management. Pharmacogenomics. 2:2001;177-194
27. Mickelson J.R., Louis C.F. Malignant hyperthermia Excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. [review] Physiol Rev. 76:1996;537-592
28. Wedel D.J. Malignant hyperthermia and neuromuscular disease. Neuromuscul Disord. 2:1992;157-164
29. Rosenbaum H.K., Miller J.D. Malignant hyperthermia and myotonic disorders. Anesthesiol Clin North Am. 20:2002;623-664
30. Rosenberg H., Shutack J.G. Variants of malignant hyperthermia. Special problems for the paediatric anaesthesiologist. Paediatr Anaesth. 6:1996;87-93
31. Robinson R., Hopkins P., Carsana A., et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet. 112:2003;217-218
32. Rosenberg H., Antognini J., Muldoon S. Testing for malignant hyperthermia. Anesthesiology. 96:2002;232-237
33. Manning B.M., Quane K.A., Ording H., et al. Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia genotype-phenotype correlation. Am J Hum Genet. 62:1998;599-609
34. Brandt A., Schleithoff L., Jurkat-Rott K., et al. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families Novel mutations and concordance with the in vitro contracture test. Hum Mol Genet. 8:1999;2055-2062
35. McCarthy T.V., Quane K.A., Lynch P.J. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat. 15:2000;410-417
36. Monnier N., Krivosic-Horber R., Payen J.-F., et al. Presence of two different genetic traits in malignant hyperthermia families Implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology. 97:2002;1067-1074
37. Kuo C.-H., Tan P.-H., Chen J.-J., et al. Prolonged paralysis associated with succinylcholine-a case report. Acta Anaesthesiol Sin. 38:2000;229-332
38. Lando G., Mosca A., Bonora R., et al. Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers An Italian-population study. Pharmacogenetics. 13:2003;265-270
39. Rosenman K.D., Guss P.S. Prevalence of congenital deficiency in serum cholinesterase. Arch Environ Health. 52:1997;42-44
40. Basta S.J. Clinical pharmacology of mivacurium chloride A review. J Clin Anesth. 4:1992;153-163
41. Hanel H.K., Viby-Mogensen J., Schaffalitzky de Muckadell O.B. Serum cholinesterase variants in the Danish population. Acta Aneasthesiol Scand. 22:1978;505-507
42. Jensen F.S., Skovgard L.T., Viby-Mogensen J. Identification of human plasma cholinesterase variants in 6, 688 individuals using biochemical analysis. Acta Aneasthesiol Scand. 39:1995;157-162
43. Cerf C., Mesguish M., Gabriel I., et al. Screening patients with prolonged neuromuscular blockade after succinylcholine and mivacurium. Anesth Analg. 94:2002;461-466
44. Gätke M.R., Viby-Mogensen J., Bundgaard J.R. Rapid simultaneous genotyping of the frequent butyrylcholinesterase variants Asp70Gly and Ala539Thr with fluorescent hybridization probes. Scand J Clin Lab Invest. 62:2002;375-383
45. Barta C., Sasvari-Szekely M., Devai A., et al. Analysis of mutations in the plasma cholinesterase gene of patients with a history of prolonged neuromuscular block during anesthesia. Mol Genet Metab. 74:2001;484-488
46. Yen T., Nightingale B.N., Burns J.C., et al. Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. Clin Chem. 49:2003;1297-1308
47. Nelson D.R., Kamataki T., Waxman D.J., et al. The P450 superfamily Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol. 12:1993;1-51
48. Linder M.W., Valdes R. Jr. Pharmacogenetics in the practice of laboratory medicine. Mol Diagn. 4:1999;365-379
49. Leathart J.B.S., London S.J., Steward A., et al. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 8:1998;529-541
50. Zimmerman T., Schlenk R., Pfaff G., et al. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers. Arzneimittelforschung. 45:1995;41-43
51. Lovlie R., Daly A.K., Molven A., et al. Ultrarapid metabolizers of debrisoquine Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 392:1996;30-34
52. Linder M.W., Looney S., Adans J.E., et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. L Thromb Thrombolysis. 14:2002;227-232
53. Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 287:2002;1690-1698
54. Felix C.A., Walker A.H., Lange B.J., et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci. 95:1998;13176-13181
55. Paris P.L., Kupelian P.A., Hall J.M., et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 8:1999;901-905
56. Petros W. Associations between variants in several drug metabolism genes and chemotherapy pharmacokinetics and clinical response. Proc AACR. 42:2001;1435
57. Tayeb M.T., Clark C., Sharp L., et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 9:2002;653-655
58. Sata F., Sapone A., Elizondo G., et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12 Evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 67:2000;48-56
59. Lee S.J., Usmani K.A., Chanas B., et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics. 13:2003;461-472
60. Keuhl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 27:2001;383-391
61. Lamba J.K., Lin Y.S., Schuetz E.G., et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Delivery Rev. 54:2002;1271-1294
62. King B.P., Leathart J.B., Mutch E., et al. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol. 55:2003;625-629
63. Borst P., Evers R., Kool M., et al. A family of drug transporters the multidrug resistance-associated proteins. J Natl Cancer Inst. 92:2000;1295-1302
64. Choo E.F., Leake B., Wandel C., et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 28:2000;655-660
65. Brinkmann U., Roots I., Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1 Impact of polymorphisms on pharmacotherapy. Drug Discov Today. 6:2001;835-839
66. Rao V.V., Dahlheimer J.L., Bardgett M.E., et al. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal fluid drug-permeability barrier. Proc Natl Acad Sci USA. 96:1999;3900-3905
67. Schinkel A.H., Wagenaar E., Mol C.A., et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 97:1996;2517-2524
68. Schaeffeler E., Eichelbaum M., Brinkmann U., et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 358:2001;383-384
69. Hitzl M., Drescher S., van der Kuip H., et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 11:2001;293-298
70. Verstuyft C., Schwab M., Schaeffeler E., et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 58:2003;809-812
71. Neuhoff S., Langguth P., Dressler C., et al. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein Drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther. 384:2000;168-179
72. Adachi Y., Suzuki H., Sugiyama Y. Quantitative evaluation of the function of small intestinal P-glycoprotein Comparative studies between in situ and in vitro. Pharm Res. 20:2003;1163-1169
73. Klotz U. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung. 52:2002;155-161
74. Skarke C., Jarrar M., Schmidt H., et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics. 13:2003;651-660
75. Kelsen S.G., Aksoy M.O., Brennan K., et al. Chronic effects of inhaled albuterol on beta-adrenoceptor system function in human respiratory cells. J Asthma. 37:2000;361-370
76. 2-adrenergic recepor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 8:1993;334-349
77. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 97:2000;10483-10488
78. 2- adrenoceptor gene polymorphism on pressor response during laryngosopy and tracheal intubation. Aneasthesia. 57:2002;227-232
79. Kaye D.M., Smirk B., Williams C., et al. β-Adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 13:2003;379-382
80. 2-adrenergic receptor stimulation. Pharmacogenetics. 13:2003;535-541
81. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 350:1997;995-999
82. Iyer L., King C.D., Whitington P.F., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11) Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 101:1998;847-854
83. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 33:1994;9414-9419
84. 2-adrenoreceptor gene are associated with decreased airway responsiveness. Clin Exp Allergy. 29:1999;1195-1203
85. Truong W., Cheng C., Xu Q.G., et al. Mu opioid receptors and analgesia at the site of a peripheral nerve injury. Ann Neurol. 53:2003;366-375
86. Dickenson A.H., Sullivan A.F., McQuay H.J. Intrathecal etorphine, fentanyl and buprenorphine on spinal nociceptive neurones in the rat. Pain. 42:1990;227-234
87. Pan Y.X., Xu J., Mahurter L., et al. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci U S A. 98:2001;14084-14089
88. Kraus J., Börner C., Giannini E., et al. Regulation of the μ-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem. 276:2001;43901-43908
89. Uhl G.R., Sora I., Wang Z. The μ opiate receptor as a candidate gene for pain Polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA. 96:1999;7752-7755
90. Hölt V. A polymorphism (A118G) in the μ-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics. 12:2002;1-2
91. Lötsch J. Does the A188G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology. 97:2002;814-819
92. Lötsch J., Skarke C., Grösch S., et al. The polymorphism A188G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 12:2002;3-9
93. Macleane G.J., Cooper R. Nature of preoperative anxiety. Anaesthesia. 45:1990;153-155
94. Macario A., Weinger M.N., Truong P., et al. Which clinical outcomes are both common and important to avoid? The perspective of a panel of expert anesthesiologists. Anesth Analg. 88:1999;1085-1091
95. Kerssens C., Klein J., Bonke B. Awareness Monitoring versus remembering what happened. Anesthesiology. 99:2003;570-575
96. Sonner J.M., Gong D., Eger E.I. 2nd. Naturally occurring variability in anesthetic potency among inbred mouse strains. Anesth Analg. 91:2000;720-726
97. Servin F.S., Bougeois B., Gomeni R., et al. Pharmacokinetics of propofol administered by target-controlled infusion to alcoholic patients. Anesthesiology. 99:2003;576-585
98. Hyatt B., Bensky K.P. Illicit drugs and anesthesia. CRNA. 10:1999;15-23
99. Liem E.B., Lin C.-M., Suleman M.-I., et al. Increased anesthetic requirement in subjects with naturally red hair. Anesthesiology. 97:2002;A-77. (abstr)
100. Seefelder C., Leeder J.S. Cytochrome P450 pharmacogenetics and anaesthesia. Paediatr Anaesth. 12:2002;810-811
101. Singh H. Bispectral index (BIS) monitoring during propofol-induced sedation and anaesthesia. Eur J Anaesthesiol. 16:1999;31-36
102. Vereecke H.E., Struys M.M., Mortier E.P. A comparison of bispectral index and ARX-derived auditory evoked potential index in measuring the clinical interaction between ketamine and propofol anaesthesia. Anaesthesia. 58:2003;957-961
103. Uezono S., Kamata A., Nagata O., et al. Intraoperative awareness and the depth of anesthesia in children A perspective from pediatric anesthesia. Sleep Med. 3:(suppl 2):2002;S67-70
104. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients A meta-analysis of prospective studies. JAMA. 279:1998;1200-1205
105. Phillips K.A., Veenstra D.L., Oren E., et al. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA. 286:2001;2270-2279
106. Meisel C., Roots I., Cascorbi I., et al. How to manage individualized drug therapy Application of pharmacogenetic knowledge of drug metabolism and transport. Clin Lab Med. 38:2000;869-876
107. Kirchheiner J., Brosen K., Dahl M.L., et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants A first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 104:2001;173-192
108. Brockmoller J., Kirchheiner J., Meisel C., et al. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenetics. 1:2000;125-151
109. Hoffman B.B. Adrenoceptor antagonist drugs. Katzung BG. Basic and Clinical Pharmacology. ed 7:1997;McGraw-Hill Professional, New York, NY
110. Laurent-Kenesi M.A., Funck-Brentano C., Poirier J.M., et al. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol. 366:1993;531-538
111. Zhou H.H., Wood A.J. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther. 575:1995;518-524
112. Mehvar R., Brocks D.R. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. Pharm Pharmaceut Sci. 42:2001;185-200
113. Neuhoff S., Langguth P., Dressler C., et al. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein Drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther. 38:2000;168-179
114. Edeki T.I., He H., Wood A.J. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA. 27420:1995;1611-1613
115. Yoshimoto K., Echizen H., Chiba K., et al. Identification of human cyp isoforms involved in the metabolism of propranolol enantiomers-N- desisopropylation is mediated mainly by CYP1a2. Br J Clin Pharmacol. 39:1995;421-431
116. Lasocki S., Iglarz M., Seince P.-F., et al. Involvement of renin-angiotensin system in pressure-flow relationship. Aneasthesia. 96:2002;271-275
117. O'Toole L., Stewart M., Padfield P., et al. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol. 32:1998;988-994
118. Penno G., Chaturvedi N., Talmud P.J., et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients Findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes. 47:1998;1507-1511
119. Sciarrone M.T., Stella P., Barlassina C., et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension. 41:2003;398-403
120. Siffert W. Cardiovascular pharmacogenetics On the way toward individually tailored drug therapy. Kidney Int Suppl. 84:2003;S168-171
121. Molden E., Johansen P.W., Boe G.H., et al. Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. Clin Pharmacol Ther. 72:2002;333-342
122. Tracy T.S., Korzekwa K.R., Gonzalez F.J., et al. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol. 47:1999;545-552
123. Harris R., Jang G., Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 42:2003;1071-1088
124. Scherling D., Karl W., Ahr G., et al. Pharmacokinetics of nisoldipine III. Biotransformation of nisoldipine in rat, dog, monkey, and man. Arzneimittelforschung. 38:1988;1105-1110
125. Krol G.J., Lettieri J.T., Yeh S.C., et al. Disposition and pharmacokinetics of 14C-nitrendipine in healthy volunteers. J Cardiovasc Pharmacol. 9:1987;122-128
126. Uchida S., Watanabe H., Nishio S., et al. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. Clin Pharmacol Ther. 74:2003;505-508
127. Kurland L., Melhus H., Karlsson J., et al. Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Angiotensin-converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens. 19:2001;1783-1787
128. Marino M.R., Vachharajani N.N. Drug interactions with irbesartan. Clin Pharmacokinet. 40:2001;605-614
129. Yasar U., Forslund-Bergengren C., Tybring G., et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 71:2002;89-98
130. Diovan (valsartan) package insert #T2002-77. 2002;Novartis Pharmaceuticals Corporation, East Hanover, NJ
131. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 97:2000;3473-3478
132. Hamilton R.A., Kowalsky S.F., Wright E.M., et al. Effect of the acetylator phenotype on amrinone pharmacokinetics. Clin Pharmacol Ther. 40:1986;615-619
133. Schmitz G., Drobnik W. Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin Chem Lab Med. 41:2003;581-589
134. Buchert E., Woosley R.L. Clinical implications of variable antiarrhythmic drug metabolism. Pharmacogenetics. 2:1992;2-11
135. Schwartz P.J., Priori S.G., Locati E.H., et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 92:1995;3381-3386
136. Labbe L., O'Hara G., Lefebvre M., et al. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther. 68:2000;44-57
137. Lee J.T., Kroemer H.K., Silberstein D.J., et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med. 322:1990;1764-1768
138. Kobayashi K., Nakajima M., Chiba K., et al. Inhibitory effects of antiarrhythmic drugs on phenacetin O-demethylation catalysed by human CYP1A2. Br J Clin Pharmacol. 45:1998;361-368
139. Almog S., Shafran N., Halkin H., et al. Mechanism of warfarin potentiation by amiodarone Dose- and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol. 28:1985;257-261
140. Okumura K., Kita T., Chikazawa S., et al. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther. 61:1997;509-517
141. Aiba T., Takehara Y., Okuno M., et al. Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats. Pharm Res. 20:2003;745-748
142. Bertelsen K.M., Venkatakrishnan K., Von Moltke L.L., et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine Comparison with fluoxetine and quinidine. Drug Metab Dispos. 31:2003;289-293
143. Priori S.G., Barhanin J., Hauer R.N., et al. Genetic and molecular basis of cardiac arrhythmias Impact on clinical management part III. Circulation. 99:1999;674-681
144. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms A comprehensive review of the in-vitro and human data. Pharmacogenetics. 12:2002;251-263
145. Nelson D.R., Koymans L., Kamataki T., et al. P450 superfamily Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42
146. Wilson J.F., Weale M.E., Smith A.C., et al. Population genetic structure of variable drug response. Nat Genet. 29:2001;265-269
147. Lennard L., Silas J.H., Freestone S., et al. Oxidation phenotype - A major determinant of metoproplol metabolism and response. N Engl J Med. 307:1982;1558-1560